RCC Management and Biomarkers Discussed at NCS AUA 2026 Meeting
At the 2026 North Central Section of the American Urological Association annual meeting, clinicians examined how renal cell carcinoma management is changing, focusing on the friction between expanding adjuvant systemic therapies and the lack of reliable predictive biomarkers to guide them, UroToday reported. While conventional clinicopathologic characteristics remain the foundation of risk stratification, emerging data show that standard staging alone fails to capture the biologic heterogeneity of kidney cancer, leaving physicians to weigh marginal disease-free survival gains against substantial treatment-related toxicities.
Adjuvant Trials Show Varying Outcomes for Renal Cell Carcinoma
Dr. Vidit Sharma opened the panel by reviewing five major adjuvant trials in renal cell carcinoma, highlighting stark disparities in trial designs and clinical outcomes. KEYNOTE-564 evaluated one year of pembrolizumab and demonstrated improvements in both disease-free survival and overall survival. More recently, LITESPARK-022 evaluated pembrolizumab combined with belzutifan, showing a disease-free survival benefit while overall survival data remain immature. In contrast, IMmotion010 evaluating atezolizumab, CheckMate-914 evaluating ipilimumab plus nivolumab, and PROSPER evaluating a perioperative nivolumab strategy all failed to demonstrate improvements in disease-free survival or overall survival.
These divergent findings indicate that adjuvant immunotherapy benefits do not constitute a uniform class effect. Therapeutic efficacy depends heavily on specific treatment regimens, patient populations, and trial structures. These benefits arrive alongside notable toxicity burdens. In KEYNOTE-564, an absolute disease-free survival benefit of 8.7% at five years was accompanied by a 17.4-percentage-point increase in grade 3 or higher adverse events compared with the placebo arm. LITESPARK-022 saw a 4.6% disease-free survival improvement paired with a 21.9-percentage-point increase in severe toxicity.
Because not every patient undergoing nephrectomy experiences recurrence, many individuals endure significant adverse events without deriving clinical benefit. Subgroup analyses from KEYNOTE-564 demonstrate that baseline risk dictates absolute treatment effect. Intermediate-high risk patients achieved a 24-month disease-free survival rate of 81.1% with pembrolizumab versus 72.0% with placebo. High-risk populations saw rates of 48.7% and 35.4% respectively, while the M1 NED population reached 78.4% compared to 37.9%. A risk-adapted framework proposed by Das and colleagues models this dynamic, showing that absolute benefit shrinks as expected disease-free survival on surveillance increases.
Researchers Investigate Prognostic Tools to Refine Patient Selection
To refine patient selection, researchers are investigating diverse prognostic tools spanning clinical nomograms, urine-based assays, blood and plasma markers, tissue signatures, radiographic features, immunologic biomarkers, and the microbiome. Clinical risk groups remain the most practical baseline. The American Urological Association categorizes low-risk disease as pT1 tumors with grade 1 or 2 histology, intermediate risk as pT1 grade 3 or 4 or pT2 tumors, and high risk as pT3 lesions. Very-high-risk classifications involve pT4 or pN1 disease, sarcomatoid or rhabdoid differentiation, or macroscopic positive surgical margins. Mayo Clinic validation studies published in 2024 demonstrated that these classifications provide meaningful progression-free survival separation, with the Mayo model yielding an area under the curve of 0.82 compared to 0.78 for the standard AUA classification.
Circulating biomarkers such as plasma kidney injury molecule-1 offer additional prognostic insight. Xu and colleagues evaluated preoperative plasma KIM-1 in 2024, finding that baseline concentrations correlate with metastasis-free survival following nephrectomy.
Biomarker analyses from IMmotion010 suggest that baseline KIM-1 levels can identify differential treatment outcomes, where patients with high KIM-1 levels derived disease-free survival benefits from atezolizumab while low-KIM-1 cohorts did not. These findings highlight the shift toward individualized risk stratification, though integrating these complex biomarker panels into routine clinical workflows is a central challenge for oncology practices.